Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 6:16:17588359241236451.
doi: 10.1177/17588359241236451. eCollection 2024.

Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Jean-Bernard Auliac  1 , Pascal-Alexandre Thomas  2 , Olivier Bylicki  3 , Florian Guisier  4 , Hubert Curcio  5 , AlainVegnenègre  6 , Aurelie Swalduz  7 , Marie Wislez  8 , Jacques Le Treut  9 , Chantal Decroisette  10 , Victor Basse  11 , Lionel Falchero  12 , Gonzague De Chabot  13 , Diane Moreau  14 , Eric Huchot  15 , Audrey Lupo Mansuet  16 , Helene Blons  17 , Christos Chouaïd  18 , Laurent Greillier  19
Affiliations

Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study)

Jean-Bernard Auliac et al. Ther Adv Med Oncol. .

Abstract

Background: Few epidemiological data are available on surgically treated Caucasian patients with non-small-cell lung cancers (NSCLCs) harboring epidermal growth factor receptor (EGFR) mutations. The main objective of this study was to describe, in the real-world setting, these patients' incidence, clinical, and tumoral characteristics.

Methods: The participating centers included all consecutive localized non-squamous NSCLC patients undergoing surgery between January 2018 and December 2019 in France. EGFR status was determined retrospectively when not available before surgery.

Results: The study includes 1391 no squamous NSCLC patients from 16 centers; EGFR status was determined before surgery in 692 (49.7%) of the cases and conducted as part of the study for 699 (50.3%); 171 (12.3%) were EGFR mutated; median age: 70 (range: 36-88) years; female: 59.6%; never smokers: 75.7%; non-squamous histology 97.7%, programmed death ligand-1 expression 0%/1-49%/⩾50 in 60.5%/25.7%/13.8%, respectively. Surgery was predominantly lobectomy (81%) or segmentectomy (14.9%), with systematic lymph node dissection in 95.9%. Resection completeness was R0 for 97%. Post-surgery staging was as follows: IA: 52%, IB: 16%, IIA: 4%, IIB: 10%, IIIA: 16%, and IIIB: 0.05%; EGFR mutation exon was Del19/exon 21 (L858R)/20/18 in 37.4%/36.8%/14%, and 6.4% of cases, respectively; 31 (18%) patients received adjuvant treatment (chemotherapy: 93%, EGFR tyrosine kinase inhibitor: 0%, radiotherapy: 20%). After a median follow-up of 31 (95% confidence interval: 29.6-33.1) months, 45 (26%) patients relapsed: 11/45 (24%) locally and 34 (76%) with metastatic progression. Median disease-free survival (DFS) and overall survival were not reached and 3-year DFS was 60%.

Conclusion: This real-world analysis provides the incidence and outcomes of resected EGFR-mutated NSCLCs in a European patient cohort.

Keywords: EGFR mutation; lung cancer management; surgery.

PubMed Disclaimer

Conflict of interest statement

J-BA: In the last 5 years, J-BA has received honoraria for attending scientific meetings, speaking, organizing research, or consulting, from Boehringer Ingelheim, Hoffman-Roche, Takeda, BMS, MSD, Astra Zeneca, Amgen, and Pfizer.

References

    1. Debieuvre D, Molinier O, Falchero L, et al..; Study Group KBP-2020-CPHG; KBP-2020-CPHG. Lung cancer trends and tumor characteristic changes over 20 years (2000–2020): results of three French consecutive nationwide prospective cohorts’ studies. Lancet Reg Health Eur 2022; 22: 100492. - PMC - PubMed
    1. Postmus PE, Kerr KM, Oudkerk M, et al..; on Behalf of the ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–iv21. - PubMed
    1. Singh N, Temin S, Baker S, Jr, et al.. Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO living guideline. J Clin Oncol 2022; 40: 3310–3322. - PubMed
    1. Pignon JP. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008; 26: 3552–3559. - PubMed
    1. Le Pechoux C, Pourel N, Barlesi F, et al.. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (lung ART): an open-label, randomised, phase 3 trial. Lancet Oncol 2022; 23: 104–114. - PubMed